真核生物胞质伴侣素6A在非小细胞肺癌中的异常表达及临床意义

Abnormal expression of chaperonin containing TCP1 subunit 6A in non-small cell lung cancer and its clinical significance

目的评估真核生物胞质伴侣素6A(CCT6A)在非小细胞肺癌(NSCLC)癌组织中的表达情况,并探讨其与NSCLC患者临床病理特征和预后的关联。方法回顾性纳入160例接受手术切除治疗的NSCLC患者,收集其临床病历资料及随访信息。收集所有患者的手术切除样本(包括160例癌组织样本及50例癌旁组织样本),采用免疫组织化学染色检测CCT6A表达水平。比较不同临床病理特征的NSCLC患者癌组织中CCT6A表达水平的差异。根据CCT6A表达水平将患者分为低表达组(n=70)和高表达组(n=90),通过生存分析和多因素Cox回归分析探讨CCT6A表达与预后的关系。结果CCT6A主要表达于细胞质和细胞膜,其在癌组织中的表达水平高于癌旁组织[(4.8±2.9)分vs(2.5±1.7)分,P<0.01]。癌组织中CCT6A表达水平与NSCLC患者的年龄、性别、吸烟史、饮酒史、高血压病史、高脂血症史、糖尿病史、肿瘤大小、肿瘤病理类型、TNM分期等临床病理特征无关(P均>0.05),但东部肿瘤协作组体力状态(ECOGPS)评分高、肿瘤分化差、有淋巴结转移的患者癌组织中CCT6A表达水平分别高于ECOG PS评分低、肿瘤分化好、无淋巴结转移的患者(P均<0.05)。癌组织CCT6A高表达组患者的无病生存期和总生存期均短于癌组织CCT6A低表达组(P均<0.05)。多因素Cox回归分析结果显示,癌组织CCT6A高表达是无病生存期差的独立预测因素(P=0.001),但不是总生存期的独立预测因素。结论CCT6A在NSCLC组织中高表达,其高表达与NSCLC患者肿瘤分化差、淋巴结转移、ECOGPS评分高有关,并且可预测复发风险。

Objective To evaluate the expression of chaperonin containing TCP1 subunit 6A(CCT6A)in non-small cell lung cancer(NSCLC)tissue,and explore its correlation with the clinicopathological features and prognosis of NSCLC patients.Methods A total of 160 NSCLC patients who underwent surgical resection were retrospectively enrolled,and their clinicopathological data and follow-up information were collected.The surgical resection samples of all patients(including 160 cases of cancer tissue samples and 50 cases of adjacent tissue samples)were collected,and the expression of CCT6A was detected by immunohistochemistry.The expression of CCT6A in cancer tissue of NSCLC patients with different clinicopathological characteristics was compared.The patients were divided into low expression group(n=70)and high expression group(n=90)according to the expression level of CCT6A.The relationship between the expression of CCT6A and prognosis was discussed by survival analysis and multivariate Cox regression analysis.Results CCT6A was mainly expressed in the cytoplasm and cell membrane,and its expression level in the cancer tissue was significantly higher than that in the adjacent tissue(4.8±2.9 vs 2.5±1.7,P<0.01).The expression level of CCT6A was not correlated with clinicopathological characteristics of patients,such as age,gender,smoking,drinking,hypertension,hyperlipidemia,diabetes mellitus,tumor size,histological type,or TNM stage(all P>0.05).However,the expression levels of CCT6A in cancer tissue of patients with high Eastern Cooperative Oncology Group performance status(ECOG PS)score,poor tumor differentiation,or lymph node metastasis were significantly higher than those of patients with low ECOG PS score,good tumor differentiation,or no lymph node metastasis(all P<0.05).In addition,disease-free survival(DFS)and overall survival(OS)were significantly shorter in patients with high CCT6A expression in cancer tissue than in patients with low CCT6A expression(both P<0.05).Multivariate Cox regression analysis showed that high expression of CCT6A in cancer tissue was an independent predictor of poor DFS(P=0.001),but not an independent predictor of OS.Conclusion CCT6A is highly expressed in NSCLC tissue,and its high expression is associated with poor tumor differentiation,lymph node metastasis,and high ECOG PS score in NSCLC patients,and can be used to predict the risk of recurrence.